Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
University Hospital, Grenoble
Roswell Park Cancer Institute
Case Comprehensive Cancer Center
NextPoint Therapeutics, Inc.
Adlai Nortye Biopharma Co., Ltd.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
DNAtrix, Inc.
Bellicum Pharmaceuticals
Beijing Tsinghua Chang Gung Hospital
Akita University Hospital
Envita Medical Center, Inc.